A gas chromatography -mass spectrometric (GC -MS) method was developed and validated for the simultaneous detection and quantification in postmortem whole blood samples of cocaine (COC), amphetamines (AMPs) and cannabis; the main drugs involved in cases of impaired driving in Brazil. The analytes were extracted by solidphase extraction by means of Bond-Elute Certify cartridges, derivatized with N-methyl-N-(trimethylsilyl)trifluoroacetamide at 808 8 8 8 8C for 30 min and analyzed by GC -MS. Linearity ranged from 10 to 500 ng/mL, except for ecgonine methyl ester, for which linearity ranged from 10 to 100 ng/mL. Inter-and intra-day imprecision ranged from 2.8 to 18.4% and from 1.5 to 14.9%, respectively. Accuracy values lay between 86.9 and 104.4%. The limit of quantitation for all drugs was 10 ng/mL and recoveries were >74% for all analytes, except for cannabinoids, which showed poor recovery (∼30%). The developed method was applied to real samples collected from deceased victims due to traffic accidents. These samples were selected according to the results obtained in immunoassay screening on collected urine samples. Five samples were positive for the presence of COC and metabolites, four samples were positive for cannabinoids, six samples were positive for AMPs and two samples were drug negative. Some samples were positive for more than one class of drug. Results obtained from whole blood samples showed good agreement with urine screening. The developed method proved capable of quantifying all three classes of drugs of abuse proposed in this study, through a one-step extraction procedure.
Introduction
The screening of drugs of abuse in biological samples is essential in forensic toxicology. However, the drugs that are searched for can vary depending on the context from which the analyzed samples are taken. Cases from clinical toxicology, workplace drug testing, doping analysis or forensic toxicology, for instance, can be used to target different drugs or classes of drugs (1 -3) .
Thus, these screening procedures can be aimed at either a relatively small number of drugs and metabolites in accordance with previous case history or alternatively they can be geared to a broader number of substances in a systematic toxicological analysis (2, (4) (5) (6) (7) (8) (9) (10) . More recently, techniques based on high-resolution mass spectrometry have been used for this purpose (11, 12) .
A sample of choice can vary depending on the context of the investigated cases, but the most common specimens used for drug screening are serum/plasma, whole blood, bile and urine (5, 13) . Whole blood is the matrix most frequently encountered in forensic toxicology, mainly in cases of deceased victims, where the preparation of serum or plasma is often impossible (7, 14) . Whole blood is also the recommended sample collected in cases of driving under the influence of drugs (DUIDs), since whole blood is known as the sample of choice for the quantification and correlation of drug abuse with impaired driving (2, 3, 7, (15) (16) (17) (18) (19) .
Although the use of whole blood is critical to the field of forensic toxicology, especially in postmortem cases, the higher viscosity of whole blood compared with serum/plasma can cause certain limitations, particularly in terms of extraction procedures. In order to overcome this, pretreatment of whole blood is usually necessary and can be carried out using different methods; protein precipitation through a pH adjustment, acid treatment, inorganic salt treatment or use of a polar solvent or performing blood dilution with an appropriate buffer solution (2, 5, 14) . Consequently, the development of an analytical method depends on the choice and optimization of the extraction method, thus directly impacting on the method's sensitivity and selectivity (4, 5, 20) .
In general, the extraction techniques most used for nonvolatile substances are liquid-liquid extraction (LLE) and solidphase extraction (SPE) (4, 5, 20) . LLE techniques also have well-known disadvantages and have been substituted for SPE which can provide clean extracts without the disadvantages presented by LLEs, allowing successful recovery and reproducible results (4, 6, 7, 19, 20) .
Different types of adsorbents can be used for SPE cartridges, such as C18, silica, alumina, cation-and anion exchange. However, mixed-mode adsorbents present an interesting alternative, avoiding two extraction procedures. Mixed-mode adsorbents combining cation-or anion exchange with a hydrophobic or polymeric adsorbent can simultaneously extract neutral, basic and acidic drugs (4, 5, 20, 21) . In this study, a mixed-mode adsorbent with both hydrophobic and cationexchange properties was used.
The use of a mixed-mode cartridge allows the extraction of acidic, neutral and basic drugs using a single column. This is also a great advantage in forensic toxicology, as samples available for analysis are often very limited (7) .
Many SPE procedures are geared for the extraction of a single drug or a single class of drugs from a relatively clean biological sample such as plasma, serum or urine. These methods are generally not suitable for forensic applications, where possible analytes present in samples are unknown and samples are not usually as clean and interferent-free (6) .
The objective of the present study was to develop a singleextraction procedure to be applied in DUID cases, for the detection and quantification of the main drugs involved in such contexts in Brazil; specifically, cocaine (COC), amphetamines (AMPs) and cannabis (22 -25) .
Methods

Reagents and solutions
Acetone, acetic acid, chloroform, ethyl acetate and methanol, all of which high-performance liquid chromatography (HPLC) grades, were purchased from JT Baker (USA); ammonium hydroxide, reagent grade, was purchased from Synth (Diadema, Brazil); potassium dihydrogen phosphate (KH 2 PO 4 ) and disodium hydrogen phosphate (Na 2 HPO 4 ), both ACS grades, were obtained from Vetec (Duque de Caxias, Brazil).
Phosphate buffer 0.1 M was prepared by dissolving 1.18 g of Na 2 HPO 4 in (A) 100 mL of water and 9.078 g of KH 2 PO 4 (B) in 1,000 mL of water. Finally, 50 mL of (A) was mixed with 950 mL of (B) to obtain a pH 6.0.
All drugs and metabolites were acquired from Cerilliant (Round Rock, TX, USA) as acetonitrile or methanol solutions at a concentration of 1 mg/mL. The only exception was fenproporex that was donated in the powder form (99.9%) by AcheṔ harmaceutical Laboratories S.A. (Sa˜o Paulo, Brazil). The drugs and metabolites used in this study were the following: AMP, methamphetamine (MAMP), amphepramone, fenproporex, 3,4-methylenedioxyamphetamine (MDA), N-methyl-3,4-methylenedioxymethamphetamine (MDMA), N-ethyl-3,4-methylenedioxyethylamphetamine (MDEA), COC, cocaethylene (COE), benzoylecgonine (BE), anhydroecgonine methyl ester (AEME), ecgonine methyl ester (EME), delta-9-tetrahydrocannabinol (THC) and 11-nor-delta-9-tetrahydrocannabinol-9-carboxylic acid (THCCOOH). AMP-d 11 11 was the IS used for the quantification of AMP, MDA, amphepramone and fenproporex; COC-d 3 was used for the quantification of COC, COE, AEME and EME; THCCOOH-d 3 was the IS for THC and THCCOOH.
Working standard solutions (1.0 and 10.0 mg/mL) of each compound were prepared by appropriate dilution with methanol or acetonitrile.
N-methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA), supplied by Sigma-Aldrich (Milwaukee, WI, USA), was the derivatization reagent.
Whole blood samples Blood bags, obtained from the Blood Bank and Hematology Center in Vito´ria (ES, Brazil), were tested for the presence of the aforementioned drugs and metabolites. Ten different blood samples screened negative for drugs and metabolites were pooled for use as a blank matrix, for validation purposes.
All thewhole blood sampleswere obtainedfromdeceased victims by femoral vein collection; samples were stored in gray-top tubes containing 2% of sodium fluoride and kept at 2208C until analysis.
This study was approved by the Research Ethics Committee of Health Sciences Center-Federal University of Espı´rito Santo (UFES).
Sample preparation
The extraction procedure was conducted according to Zweipfenning et al. (14) . The cartridge used for SPE was Bond-Elute Certify (Agilent Technologies, Palo Alto, CA, USA).
A volume of 1 mL of whole blood was mixed with 6 mL of phosphate buffer 0.1 M in a 15-mL centrifuge tube. IS was added in order to provide a final concentration of 100 ng/mL.
Tubes were placed on a vortex mixer for 10 s and then sonicated for 15 min at ambient temperature. Following this, samples were centrifuged for 15 min at 1055Âg.
The SPE cartridges were conditioned with 2 mL of methanol followed by 2 mL of phosphate buffer 0.1 M, carefully avoiding complete dryness of the cartridges. Samples were applied into cartridges with care, to prevent the transfer of any precipitate that could clog the cartridges. Following this, the cartridges were washed with 1 mL of water and 0.5 mL of acetic acid 0.01 M. Maximum vacuum was applied for 5 min. A volume of 50 mL of methanol was then added, and maximum vacuum was again applied for one more min.
The analytes were eluted into the same tube using two different solvent mixtures: the acidic and neutral analytes were eluted with 4 mL (2 Â 2 mL) of acetone : chloroform solution (1 : 1, v/v), and basic analytes were eluted with a freshly prepared solution of ethyl acetate : ammonium hydroxide (98 : 2, v/v).
Residues were evaporated until dryness at 408C, under a gently nitrogen stream in a dry block. A 50-mL volume of MSTFA was added to a 2-mL vial that was then capped and derivatized at 808C for 30 min. Residues were then transferred to a 200-mL insert.
Instrumentation
The analysis of the extracts was performed on a Varian CP-3800 Gas Chromatograph (Palo Alto, CA, USA) coupled with a Varian Saturn 2200 ion trap mass spectrometer. Injections (1 mL) were made in the splitless mode at 2808C. A pressure pulse of 25 psi was used for 1.1 min.
Separations were carried out in an HP-5MS capillary column (30 m Â 0.25 mm i.d., 0.25-mm film thickness). Helium was used as the carrier gas at a flow rate of 1.1 mL/min.
The column oven program was performed as follows: the initial temperature was 908C for 2 min, increased to 2208C at a rate of 108C/min and then increased to a final temperature of 2908C at a rate of 308C/min, held for 6 min (run time ¼ 23.33 min).
The mass spectrometer worked in the electron impact mode with a filament emission current of 15 mA and a multiplier offset of 200 V, and full scan mode (70 -500 m/z) for quantification. The transfer line, manifold and trap temperatures were 290, 120 and 2408C, respectively.
Data analysis
Analytes were identified and quantified using retention time (+2% tolerance) and reference spectrum information, as shown in Table I . The qualifications were based on MS ion data extracted from the total ion data during post-run analysis. Because the ion ratios on the ion trap mass spectrometer are not very reproducible, the identification was conducted by measure of similarity with reference spectrum (.70%) for each analyte. The reference spectrum was obtained from extracted whole blood samples spiked with all analytes.
Method validation
The selectivity/specificity, limit of detection (LOD), limit of quantification (LOQ), linearity, precision (intra and inter-assay), accuracy, recovery and stability parameters were assayed.
The calibrators and quality controls (QCs) were prepared by addition of known amounts of analytes and IS to the drug-free blood used as a blank matrix. The QCs were prepared at the following concentrations: 25 ng/mL (QC1-low), 200 ng/mL (QC2-medium) and 400 ng/mL (QC3-high) for all analytes, except for EME for which the QC concentrations were 25, 50 and 75 ng/mL. Selectivity/specificity These parameters were evaluated by analysis of nine samples (n ¼ 9) that were prepared by adding LOQ concentration of all analytes, 100 ng/mL of all IS and 2,000 ng/mL of 34 possible interferents. These were: oxcarbazepine, carbamazepine, dipyrone, potassium diclofenac, tramadol, sertraline, phenobarbital, venlafaxine, citalopram, barbital, amitriptyline, fluoxetine, sildenafil, flunitrazepam, diazepam, alprazolam, bromazepam, clonazepam, midazolam, meperidine, nicotine, cotinine, ephedrine, disulfiram, amobarbital, methadone, codeine, morphine, flurazepam, lorazepam, prazepam, temazepam, oxazepam and chlordiazepoxide. Ten different drug-negative bloods were used as a blank matrix.
Limit of detection and limit of quantitation LOD and LOQ were evaluated by analyzing the blank matrix fortified with decreasing analyte concentrations. LOD and LOQ were defined as the lowest concentration giving a signal/noise ratio of at least 3 and 10, respectively, besides acceptable precision [relative standard deviation (RSD) 20%] and accuracy (+20%). 
Linearity
The linearity study was performed using six levels with five replicates for each level (n ¼ 30). Calibration curves were obtained by plotting the peak area ratios (analyte/IS) against the concentrations, and the linearity was determined and expressed as the coefficient of determination (r 2 ).
Precision and accuracy
Precision was measured as the RSD%, and accuracy was expressed as the percentage of the target concentration of analytical results obtained from independently prepared QC standards.
The precision and accuracy assay were performed by analyzing at least five replicates at three different concentration levels (CQ1, CQ2 and CQ3).
Inter-assay precision was determined on three consecutive days (n ¼ 45), and intra-assay precision was calculated from 10 replicate determinations per concentration in one assay batch. Data were evaluated by examining the variance in each group (intra-and inter-day), which were established by the RSD%. The RSD values should be better than 20% for CQ1 and better than 15% for CQ2 and CQ3. Accuracy was determined by comparing measured concentrations with target values and expressed as the percentage of the target concentration. Accuracy values should fall within +20% of the expected value for CQ1 and within +15% for CQ2 and CQ3.
Recovery
The recovery or extraction efficiency of the method was assessed by analysis of five blank matrix replicates, to which analytes were added at each concentration level (CQ1, CQ2 and CQ3) before the extraction procedure (n ¼ 15). These samples were compared with non-extracted samples, to which analytes were added after the extraction procedure. In both sets of samples (extracted and non-extracted), the IS (100 ng/mL) was added prior to the SPE procedure. The recovery values should provide adequate LOQs for the method's purpose.
Carryover
To evaluate carryover, blank injections were made after the injection of the highest concentration level of the calibration curve.
Stability
Stability was assessed using triplicates of the blank matrix fortified with all analytes at low and high concentration levels (CQ1 and CQ3). The following stability tests were then performed: storage at 2208C (30 and 90 days); freeze -thaw cycles and processed sample stability (24, 48 and 72 h).
Results from stability samples were compared against freshly prepared samples analyzed in the same analytical runs, and variation for all analytes should fall within +15% of the latter. Results and Discussion
GC-MS method
In agreement with other authors (26, 27) , MSTFA was the agent of choice in the present work. Despite MSTFA producing relatively low m/z ions in the MS spectra of AMPs, it showed good reactivity for all the reactive groups (amine, aromatic and aliphatic hydroxyl, and carboxyl moieties), unlike the other tested agents.
All analytes presented good chromatographic separation without interference, as shown in Figure 1 . Figure 2 shows a realsample chromatogram.
Selectivity/specificity All samples were evaluated in agreement with retention times (analytes and IS) and with acceptable variation (+20%) of the LOQ true value. No interference at a significant level was observed. Peaks with areas below the LOQ were rejected, identified as interfering peaks (Figures 3 and 4 ).
Limit of detection and limit of quantitation LOD and LOQ were 5 and 10 ng/mL, respectively, for all analytes (Table II) .
Linearity
The working range assumed for all analytes was 10-500 ng/mL (10, 25, 50, 100, 250 and 500 ng/mL), except for EME, which was 10 -100 ng/mL to maintain the linearity requirements.
As occurred with Peres et al. (28) , the most appropriated calibration model was the linear regression with 1/x weighting. All curves showed r 2 .0.99 (Table II) .
Precision and accuracy
Precision and accuracy results for all analytes were satisfactory. Accuracy values ranged from 86.9 to 104.4 (% bias). Intra-day imprecision ranged from 1.5 to 14.9 (%RSD), and inter-day imprecision ranged from 2.8 to 18.4% (%RSD) ( Table III) .
Recovery
The recovery tests yielded values .74% (mean recovery) for all analytes, except for cannabinoids that presented poor recovery in agreement with Peres et al. (28) (Table IV) . Nevertheless, the low cannabinoid recovery values ( 30%) obtained were sufficient for the goals proposed in the present work.
Carryover
There was no interference in the blank analysis performed after injection of the highest concentration level of the calibration curve (500 ng/mL). Additionally, despite the high injector temperature, AEME formation did not occur as an artifact of the thermal conversion of COC.
Stability
All analytes showed satisfactory stability for 90 days at 2208C storage, as well as after three freeze-thaw cycles. The processed sample stability was evaluated by reinjection of derivatized extracts and showed stability for 72 h. After this time, the volume of the extracts reduced or even dried by evaporation. Application to real samples The developed method was applied to real samples collected from victims deceased due to traffic accidents. These samples were selected according to the results obtained in urine sample immunoassays. Thus, we selected samples screened positive for the three major drug groups investigated in this work: AMPs, COC and cannabinoids, in addition to some negative samples. The results are shown in Table V . Five samples were positive for COC and EME, with concentrations ranging from ,10.0 to 125.3 ng/mL and from 13.1 to 451.2, respectively. Four samples were positive for COE, ranging from ,10.0 to 81.4 ng/mL, and two samples were positive for AEME, a marker for crack COC use, with concentrations ranging from ,10.0 to 13.2 ng/mL.
As seen in Zweipfenning et al. (14) , BE could not be extracted using the proposed procedure. However, EME successfully substituted BE as a major metabolite and COC use marker, as showed above. Further experiments indicated that use of dichloromethane/isopropanol/ammonium hydroxide solution (78 : 20 : 2, v/ v/v) as an additional elution step can recover BE to satisfactory levels.
Four samples tested positive for cannabinoids, with positivity for THCCOOH ranging from 20.2 to 144.4 ng/mL. Two of these samples were also positive for THC, with concentrations of 11.3 and 13.2 ng/mL. Six samples tested positive for drugs belonging to the AMP class. Indeed, two were positive for MAMP, with concentrations of 15.6 and 120.5 ng/mL. One sample was positive for MDMA and for its metabolite, MDA, with concentrations of 369.0 and 41.2 ng/mL, respectively. One sample was positive for fenproporex at a concentration of 158.5 ng/mL and for AMP. In this case, AMP was present as a fenproporex metabolite, with a blood concentration of 60.4 ng/mL. One sample showed positivity only for AMP (14.2 ng/mL) and another sample (sample 6), which had screened negative in urine, tested positively to amphepramone (diethylpropion) in whole blood sample. Two other samples that screened negative in urine samples were confirmed as negative by whole blood analysis.
Conclusion
The developed method proved able to detect all three classes of drugs of abuse proposed in this study.
Except for the poor recovery presented by cannabinoids, all other parameters of validation showed good results for all analytes, including nice stability outcomes.
Results obtained from whole blood samples showed good agreement with urine screening performed by immunoassay tests. Considering the fact that urine results cannot be used to determine whether an individual was under the influence of drugs, the developed method can be used successfully to confirm and quantitate results found in the urine screening. This is especially important in traffic accidents, to asses DUIDs at the moment of collision.
Since amphepramone and fenproporex are two AMP-type stimulants frequently abused by professional drivers in Brazil, this makes the development of novel methods that are able to detect these drugs highly relevant.
